Neurotoxins as Preclinical Models for Parkinson's Disease

被引:8
|
作者
Segura-Aguilar, Juan [1 ]
机构
[1] Univ Chile, Dept Mol & Clin Pharmacol, Fac Med, Santiago, Chile
关键词
Parkinson's disease; Dopamine; Preclinical models; Neurotoxins; Translational medicine; Clinical studies; Aminochrome; MPTP; 6-Hydroxydopamine; Rotenon; Neurodegeneration; DT-DIAPHORASE PROTECTS; GAMMA AGONIST PIOGLITAZONE; ALPHA-SYNUCLEIN; DOPAMINERGIC-NEURONS; SUBSTANTIA-NIGRA; CELL-LINE; AMINOCHROME TOXICITY; FUNCTIONAL RECOVERY; OXIDATIVE STRESS; MOUSE MODEL;
D O I
10.1007/s12640-017-9856-0
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Translational medicine is one of the major concerns in this century. While significant advances have been made with scientific knowledge, the translation of their promising results has not led to any new therapies. In Parkinson's disease, a long list of clinical studies, based on preclinical models with exogenous neurotoxins, has failed. Therefore, the aim of this opinion paper is to open discussion about preclinical models for Parkinson's disease based on neurotoxins.
引用
收藏
页码:870 / 877
页数:8
相关论文
共 50 条
  • [1] Neurotoxins as Preclinical Models for Parkinson’s Disease
    Juan Segura-Aguilar
    [J]. Neurotoxicity Research, 2018, 34 : 870 - 877
  • [2] PARKINSON'S DISEASE: ADVANCES IN PRECLINICAL SCREENING MODELS
    Khan, Shaheen
    Ansari, Imtiyaz
    Singh, Chandrashekhar
    Bamne, Falak
    Kapadia, Salman
    [J]. INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES AND RESEARCH, 2020, 11 (10): : 4866 - 4873
  • [3] Sleep and circadian rhythms in Parkinson's disease and preclinical models
    Hunt, Jeremy
    Coulson, Elizabeth J.
    Rajnarayanan, Rajendram
    Oster, Henrik
    Videnovic, Aleksandar
    Rawashdeh, Oliver
    [J]. MOLECULAR NEURODEGENERATION, 2022, 17 (01)
  • [4] Sleep and circadian rhythms in Parkinson’s disease and preclinical models
    Jeremy Hunt
    Elizabeth J. Coulson
    Rajendram Rajnarayanan
    Henrik Oster
    Aleksandar Videnovic
    Oliver Rawashdeh
    [J]. Molecular Neurodegeneration, 17
  • [5] Isoquinoline neurotoxins in the brain and Parkinson's disease
    Nagatsu, T
    [J]. NEUROSCIENCE RESEARCH, 1997, 29 (02) : 99 - 111
  • [6] Exogeneous modulation of adult neurogenesis in preclinical models of Parkinson's disease
    Winkler, J.
    [J]. FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2008, 22 : 20 - 20
  • [7] Parkinson's disease: towards better preclinical models and personalized treatments
    Lindholm, Dan
    Makela, Johanna
    Di Liberto, Valentina
    Mudo, Giuseppa
    Belluardo, Natale
    Eriksson, Ove
    Saarma, Mart
    [J]. CELLULAR AND MOLECULAR LIFE SCIENCES, 2016, 73 (07) : 1383 - 1385
  • [8] Effects of quercetin in preclinical models of Parkinson's disease: A systematic review
    Vian, Camila de Oliveira
    Marinho, Marcelo Augusto Germani
    Marques, Magno da Silva
    Hort, Mariana Appel
    Cordeiro, Marcos Freitas
    Horn, Ana Paula
    [J]. BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2024, 135 (01) : 3 - 22
  • [9] Parkinson’s disease: towards better preclinical models and personalized treatments
    Dan Lindholm
    Johanna Mäkelä
    Valentina Di Liberto
    Giuseppa Mudò
    Natale Belluardo
    Ove Eriksson
    Mart Saarma
    [J]. Cellular and Molecular Life Sciences, 2016, 73 : 1383 - 1385
  • [10] Genes, proteins, and neurotoxins involved in Parkinson's disease
    von Bohlen und Halbach, O
    Schober, A
    Krieglstein, K
    [J]. PROGRESS IN NEUROBIOLOGY, 2004, 73 (03) : 151 - 177